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INTRODUCTION
Breast cancer is the most common cancer in women world-
wide, and survival is strongly determined by the presence of 
distant metastases [1,2]. In the United States, as of January 
2012, 41% of female cancer survivors had a history of breast 
cancer. According to 2010 Korean statistics, breast cancer ac-
counts for 14,208 (14.3%) new cases and 102,946 (19.6%) 
prevalent cases in women [3].
Breast cancer represents the second most frequent cause of 
brain metastasis (BM) [4]. Among distant metastases, BM is 
less common than bone or visceral metastasis, but has poor 
prognosis and survival rates. Historically, survival of patients 
diagnosed with BM has been quite poor, and the median sur-
vival after BM from breast cancer in non-treated patients is re-
ported to be 1 month [5]. The incidence of symptomatic BM is 
estimated to be 10% to 16%, while autopsy diagnosis shows an 
incidence of up to 30% [6,7]. With improved systemic thera-
pies and neuroimaging, BM incidence is increasing in breast 
cancer patients. From 2005 to 2010, BM rates have increased to 
25% to 34% [2,8], and BM typically occurs in the late stages of 
metastatic breast cancer. In most cases, BM is followed by me-
tastases to other organs such as the liver, lungs, or bone. As sys-
temic therapies for control of extracranial disease improve, an 
increasing number of human epidermal growth factor receptor 
2 (HER2)-positive breast cancer patients experience prolonged 
survival and up to half develop BM over time [6-10].
Therefore, there is an increasing need to standardize initial 
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Purpose: To investigate treatment options for local control of me-
tastasis in the brain, we compared focal brain treatment (FBT) 
with or without whole brain radiotherapy (WBRT) vs. WBRT alone, 
for breast cancer patients with tumor relapse in the brain. We also 
evaluated treatment outcomes according to the subtypes. Meth-
ods: We conducted a retrospective review of breast cancer pa-
tients with brain metastasis after primary surgery. All patients re-
ceived at least one local treatment for brain metastasis. Surgery 
or stereotactic radiosurgery was categorized as FBT. Patients 
were divided into two groups: the FBT group received FBT± 
WBRT, whereas the non-FBT group received WBRT alone. Sub-
types were defined as follows: hormone receptor (HR)-positive/
human epidermal growth factor receptor 2 (HER2)-negative, HR-
positive/HER2-positive, HR-negative/HER2-positive, and triple-
negative (TN). We examined the overall survival after brain metas-
tasis (OSBM), brain metastasis-specific survival (BMSS), and 
brain metastasis-specific progression-free survival (BMPFS). Re-
sults: A total of 116 patients were identified. After a median fol-
low-up of 50.9 months, the median OSBM was 11.5 months 
(95% confidence interval, 9.0–14.1 months). The FBT group 
showed significantly superior OSBM and BMSS. However, FBT 
was not an independent prognostic factor for OSBM and BMSS 
on multivariate analyses. In contrast, multivariate analyses 
showed that patients who underwent surgery had improved 
BMPFS, indicating local control of metastasis in the brain. FBT 
resulted in better BMPFS in patients with HR-negative/HER2-
positive cancer or the TN subtype. Conclusion: We found that pa-
tients who underwent surgery experienced improved local control 
of brain metastasis, regardless of its extent. Furthermore, FBT 
showed positive results and could be considered for better local 
control of brain metastasis in patients with aggressive subtypes 
such as HER2-positive and TN.
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treatments for breast cancer BM. General treatment guidelines 
may be divided by prognosis of patients and extent of brain 
metastatic disease; however, these guidelines are not specific to 
breast cancer [11]. For limited BM (≤ 4), surgical resection or 
stereotactic radiosurgery (SRS) is used as the primary treat-
ment, and both these methods are collectively referred to as fo-
cal brain treatment (FBT). For patients with extensive BM, 
such as multiple BM or leptomeningeal metastases, palliative 
whole brain radiotherapy (WBRT) and palliative care are rec-
ommended. Systemic therapy options are considered for pa-
tients with good performance status [12]. Other prognostic 
factors associated with poor survival after BM include poor 
performance status and triple-negative (TN) subtype [13].
Consequently, more information on treatment outcome is 
needed to optimize local therapeutic strategies for patients 
with breast cancer BM. In this study, we report the results of a 
retrospective study comparing FBT± WBRT vs. WBRT alone, 
for breast cancer patients with tumor relapse in the brain. Fur-
thermore, to explore the influence of tumor biology on local 
treatment outcome, we also evaluated the effect of different 
cancer subtypes.
METHODS
Patient inclusion criteria
We retrospectively reviewed the medical records of breast 
cancer patients diagnosed with BM at Severance Hospital and 
Gangnam Severance Hospital, Yonsei University Medical Col-
lege, Seoul, Korea, between January 2005 and December 2012. 
During this period, 127 patients were diagnosed with BM, ir-
respective of other solid organ metastasis. Of these, 11 patients 
(8.7%) were treated with systemic chemotherapy only, leading 
to exclusion; therefore, 116 women were eligible for analyses. 
All reviewed patients underwent surgery for primary breast 
cancer. Patients were excluded if they had distant metastases at 
the time of initial diagnosis, incomplete pathologic results, or 
no treatment after diagnosis of BM. Additionally, patients pre-
senting with leptomeningeal seeding at initial BM diagnosis 
were excluded.
All patients had histologically confirmed adenocarcinoma of 
the breast. Clinical data gathered included patients’ character-
istics, diagnosis date, and initial tumor staging according to the 
TNM staging system (American Joint Committee on Cancer, 
7th edition, 2010). Tumor characteristics including the histo-
logic grade and immunohistochemical staining for estrogen 
receptor (ER), progesterone receptor (PR), and HER2 were in-
vestigated, along with local treatment methods for BM. The 
histologic grade was evaluated by using the Nottingham com-
bined histologic grading system, which determines the grade 
by assessing morphologic features (tubule formation, nuclear 
polymorphism, and mitotic count) and classifies tumors as 
grades I–III. The ER and PR positivity status was defined by an 
Allred score of 3–8. The HER2 status was evaluated using anti-
body staining and/or fluorescence in situ hybridization. The 
TN subtype was defined as a lack of ER, PR, and HER2 expres-
sion. These biomarkers were evaluated using tissues from the 
primary tumor. Tumors were classified into four subtypes: 
hormone receptor (HR)-positive/HER2-negative, HR-positive/
HER2-positive, HR-negative/HER2-positive, and TN. The In-
stitutional Review Board (IRB) of Severance Hospital, Korea, 
approved the study in accordance with good clinical practice 
guidelines and the Declaration of Helsinki (local IRB number: 
3-2014-0575).
Diagnosis of brain metastasis
Routine screening for BM was not performed. When clini-
cally suspected, brain magnetic resonance imaging and/or 
computerized tomography were performed to confirm the di-
agnosis of BM. The most common symptom associated with 
BM was headache, and other reported symptoms included 
mental status change, cognitive disturbance, and visual distur-
bance. We counted the number of metastatic lesions in the 
brain based on imaging taken at the initial BM diagnosis.
Local treatments
All BM patients received at least one local treatment, which 
consisted of surgery, SRS, or WBRT. They were classified into 
two types: surgery or SRS was categorized as FBT, and treat-
ment with WBRT alone was categorized as non-FBT. Depend-
ing on the type of local treatment administered, patients were 
divided into two groups: FBT and non-FBT. The FBT group 
received FBT with or without WBRT; this group was divided 
further into three subgroups: surgery, SRS, and surgery and 
SRS. The consort diagram summarizes these classifications 
(Figure 1).
Statistical analysis
Patients’ characteristics were compared using the log-rank 
test and Cox proportional hazards regression model. Overall 
survival after BM (OSBM) was defined as the time from initial 
BM diagnosis to the time of death or last follow-up. BM-spe-
cific survival (BMSS) was defined as the time from the initial 
BM diagnosis to the time of death resulting from BM. This was 
assessed by reviewing charts where the main cause of death 
was identified. Cases with evidence of BM progression prior to 
death were regarded as BM-related deaths. BM-specific pro-
gression-free survival (BMPFS) was defined as the time from 
the initial BM diagnosis to the time of BM progression. This 
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was confirmed using magnetic resonance imaging and/or 
computed tomography. Univariate survival analysis was per-
formed to identify prognostic factors using the log-rank test. 
Multivariate survival analysis was performed to assess the ef-
fects of breast cancer subtypes and other prognostic factors in-
fluencing survival using a Cox proportional hazards regression 
model. The hazard ratios for prognostic factors and the corre-
sponding 95% confidence intervals (CI) were estimated. All 
analyses were performed using the SPSS version 20.0 (IBM 
Corp., Armonk, USA) program and p-values less than 0.05 
were considered statistically significant.
RESULTS
Patient characteristics
From January 2005 to December 2012, a total of 116 breast 
cancer patients newly diagnosed with BM, who had received 
local treatment for BM were identified. The patients’ character-
istics are summarized in Table 1. The median age at diagnosis 
of initial breast cancer was 45 years (range, 25–69 years). The 
median follow-up period from initial breast cancer diagnosis 
was 50.9 months (range, 7.1–240.6 months). The median age 
at BM diagnosis was 46 years (range, 28–71 years), and the 
median time to BM after initial diagnosis was 35.4 months 
(range, 6.0–225.7 months). In the study population, 57 (49.1%) 
and 47 (40.5%) were ER- and HER2-positive, respectively, and 
40 (34.5%) had TN cancer.
The brain was the first metastatic site in 19 patients (16.3%), 
and in 97 (83.7%), BM occurred after systemic metastases. The 
major sites of systemic disease preceding BM were the lungs 
(62.1%), bone (54.3%), and liver (24.7%). At the time of BM 
diagnosis, the 19 patients (16.3%) did not have any other com-
bined metastases. Further, 51 patients (43.9%) had only one 
additional metastasis at initial BM diagnosis. Of these, the 
lungs were the most common metastatic site (20 patients, 
39.2%). Bone metastasis was observed in 15 patients (29.4%), 
and lymph node or soft tissue metastasis in 13 patients (25.5%). 
Liver metastasis was noted in three patients (5.9%). The re-
maining 46 patients (39.7%) presented with multiple metasta-
ses at the initial BM diagnosis.
Local treatments were administered according to the extent 
of BM and patients with a single metastasis received FBT. Of 
45 patients with multiple BM, 32 patients (71.1%) received 
WBRT alone (Table 2).
Treatment outcomes
Of the 116 total patients examined, 66 (56.9%) received 
Table 1. Clinicopathological characteristics
Characteristic No. (%) 
p-value 
for OSBM
p-value 
for BMSS
p-value 
for BMPFS
Age (yr) 0.154 0.117 0.307
   ≤40 35 (30.2)
   >40 81 (69.8)
Initial stage 0.609 0.723 0.959
   I/II 79 (68.1)
   III 37 (31.9)
Tumor size (cm) 0.903 0.919 0.416
   ≤2 47 (40.5)
   >2 69 (59.5)
LN metastasis 0.806 0.473 0.76
   Negative 40 (34.5)
   Positive 76 (65.5)
Histologic grade 0.8 0.031 0.086
   I/II 57 (49.1)
   III 59 (50.9)
No. of brain metastases 0.001 0.001 0.035
   Single 27 (23.2)
   Oligometastasis (2–4) 44 (37.9)
   Multiple (≥5) 45 (38.9)
ER 0.044 0.101 0.117
   Negative 59 (50.9)
   Positive 57 (49.1)
PR <0.001 0.001 0.005
   Negative 73 (62.9)
   Positive 43 (37.1)
HER2 0.944 0.716 0.728
   Negative 69 (59.5)
   Positive 47 (40.5)
Subtype 0.002 0.109 <0.001
   HR+HER2– 29 (25.0)
   HR+HER2+ 31 (26.7)
   HR–HER2+ 16 (13.8)
   Triple-negative 40 (34.5)
OSBM=overall survival after brain metastasis; BMSS=brain metastasis-spe-
cific survival; BMPFS=brain metastasis-specific progression-free survival; 
LN = lymph node; ER =estrogen receptor; PR =progesterone receptor; 
HER2=human epidermal growth factor receptor 2; HR=hormone receptor. 
Figure 1. Consort diagrams.
SRS=stereotactic radiosurgery; WBRT=whole brain radiotherapy.
127 Patients developing brain
metastasis
116 Patients received local
treatments for brain metastasis
66 Focal brain treatment±WBRT
18 Surgery
±WBRT
38 SRS
±WBRT
10 Surgery and 
SRS±WBRT
50 WBRT alone
50 Non-focal brain 
treatment±WBRT
Focal brain treatment
(surgery of SRS)
   Excluded
11 Patients treated with 
systemic therapy alone
NoYes
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FBT± WBRT for BM, while 50 (43.1%) received WBRT alone. 
In the FBT group, 18 women were treated with surgery, 38 
with SRS, and 10 with surgery and SRS (Figure 1).
At the time of analysis, 99 of the 116 patients were deceased. 
Causes of death were reviewed, and we found that most pa-
tients had died from complications due to metastatic disease. 
BM was determined to be responsible for the death of 51 pa-
tients (51.5%). Deaths due to BM included patients with evi-
dence of BM progression prior to death. Lung and liver metas-
tasis caused death in 27 (27.3%) and 15 patients (15.2%), re-
spectively. The remaining six patients (6.0%) died of underlying 
medical conditions that were not related to metastatic disease.
Overall survival after brain metastasis  
The median OSBM was 11.5 months (95% CI, 9.0–14.1 
months). The Kaplan-Meier OSBM rates at 1 and 2 years were 
48.8% (95% CI, 44.1–53.5) and 19.7% (95% CI, 15.8–23.6), re-
spectively.
The median OSBM for the FBT and non-FBT groups was 
16.8 months (95% CI, 12.0–21.6 months) and 5.7 months (95% 
CI, 0.5–11.0 months), respectively (p< 0.001, log-rank test) 
(Figure 2A). Furthermore, for patients in the FBT group, the 
median OSBM was the highest for women treated with sur-
gery (p= 0.003) (Figure 2B). ER, PR, BM number, and subtype 
were also identified as significant prognostic factors on univar-
iate analyses (Table 1). Multivariate analysis did not show bet-
ter OSBM for patients treated with FBT; however, positive PR 
and single brain lesions were associated with a better outcome 
(Supplementary Table 1).
Brain metastasis-specific survival
The median BMSS was 22.6 months (95% CI, 18.4–26.7 
months). The median BMSS for the FBT and non-FBT groups 
was 26.8 months (95% CI, 19.9–33.8 months) and 18.4 months 
Table 2. Types of local treatment according to the extent of brain me-
tastasis
Treatment
Extent of brain metastasis
p-valueSingle 
(n=27)
Oligometastasis* 
(n=44)
Multiple†
(n=45)
<0.001
Surgery 7 7 4
SRS 7 22 8
SRS+Surgery 7 3 1
WBRT alone 6 12 32
SRS=stereotactic radiosurgery; WBRT=whole brain radiotherapy.
*Number of metastasis: 2–4; †Number of metastasis: ≥5.
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Figure 2. Kaplan-Meier plots showing overall survival after brain metastasis and brain metastasis-specific progression-free survival for local treatment. 
All p-values were obtained by the log-rank test. (A) FBT vs. non-FBT, p<0.001. (B) Surgery vs. SRS vs. Surgery and SRS vs. WBRT alone, p=0.003. 
(C) FBT vs. non-FBT, p=0.152. (D) Surgery vs. SRS vs. Surgery and SRS vs. WBRT alone, p=0.001.
FBT=focal brain treatment; SRS=stereotactic radiosurgery; WBRT=whole brain radiotherapy.
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D
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(95% CI, 12.6–24.3 months), respectively (p=0.006, the log-rank 
test). On univariate analyses for BMSS, histologic grade, PR, and 
BM number were identified as significant prognostic factors (Ta-
ble 1). On multivariate analysis, FBT did not significantly prolong 
BMSS; however, the number of metastases and PR status were 
significant factors for BMSS (Supplementary Table 1).
Brain metastasis-specific progression-free survival  
The median BMPFS was 10.0 months (95% CI, 7.5–12.5 
months). The Kaplan-Meier BMPFS at 1 year was 43.5% (95% 
CI, 38.4–48.6). To identify treatment outcome according to the 
type of local treatment administered to control BM, we ana-
lyzed the BMPFS according to FBT. On univariate analyses, 
BMPFS did not correlate significantly with the FBT status (Fig-
ure 2C). However, BMPFS significantly differed according to 
four types of local treatment (Figure 2D). On multivariate 
analysis, patients who received surgery showed significantly 
improved BMPFS (hazard ratio, 0.31; 95% CI, 0.11–0.82) (Ta-
ble 3). This analysis revealed that the PR status and the extent 
of BM were also significant factors for BMPFS (Table 3).
Table 3. Multivariate analyses for brain metastasis-specific progression-
free survival    
Factor
BMPFS
Hazard ratio 95% CI p-value
Treatment 0.001
   WBRT alone Reference
   Surgery 0.31 0.11–0.82 0.018
   SRS 1.67 0.96–2.91 0.068
   SRS+Surgery 0.38 0.14–1.03 0.057
PR 0.029
   Positive Reference
   Negative 0.45 0.22–0.92
Subtype 0.645
   TN Reference
   HR+HER2– 0.68 0.31–1.52 0.349
   HR+HER2+ 0.79 0.36–1.74 0.554
   HR–HER2+ 0.66 0.31–1.40 0.277
No. of metastases in brain 0.016
   Multiple (≥5) Reference
   Single 0.73 0.36–1.45 0.364
   Oligometastasis (2–4) 0.43 0.24–0.77 0.004
BMPFS=brain metastasis-specific progression-free survival; CI=confidence 
interval; WBRT=whole brain radiotherapy; SRS=stereotactic radiosurgery; 
PR=progesterone receptor; TN=triple-negative; HR=hormone receptor; 
HER2=human epidermal growth factor receptor 2.
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Figure 3. Kaplan-Meier plots showing brain metastasis-specific progression-free survival for local treatment, subdivided by subtype. All p-values were 
obtained by the log-rank test. (A) HR+HER2–, p=0.143. (B) HR+HER2+, p=0.515. (C) HR–HER2+, p=0.025. (D) Triple-negative, p=0.001. 
HR=hormone receptor; HER2=human epidermal growth factor receptor 2; FBT=focal brain treatment; TNBC=triple-negative breast cancer.
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Treatment outcomes according to the subtypes
As shown in Table 1, OSBM and BMPFS differed signifi-
cantly with subtype. Patients with HR-positive/HER2-negative 
disease exhibited the best OSBM and BMPFS (Supplementary 
Figure 1). In contrast, patients with TN disease had the worst 
outcome. On univariate analysis, BMSS did not significantly 
differ by subtype.
To examine the prognostic effect of subtype, we compared 
treatment outcome according to FBT for each subtype. OSBM 
differed significantly with FBT in patients with HR-positive/
HER2-negative (p= 0.035) and TN (p= 0.028) subtypes (Sup-
plementary Figure 2). With respect to BMSS, the FBT group 
showed a better outcome in the TN subtype only (p= 0.004). 
Finally, BMPFS differed significantly with FBT in patients with 
the HR-negative/HER2-positive (p= 0.025) or TN (p= 0.001) 
subtypes (Figure 3).
DISCUSSION
In this study, we found that survival after BM was better in 
patients who had received FBT than WBRT alone. In addition, 
we evaluated BMSS and BMPFS to minimize selection bias as-
sociated with our retrospective design. BMSS, which was asso-
ciated with BM control, was better in patients treated with FBT. 
In addition, BMPFS, which directly reflects BM control, was 
prolonged in patients who underwent surgery, independent of 
the BM and PR status.
Furthermore, we evaluated treatment outcome according to 
the subtypes. In concordance with previous reports, patients 
with TN disease exhibited the worst OSBM and BMPFS, and 
surprisingly, FBT prolonged both BMSS and BMPFS. These 
findings were translated into an enhanced OSBM, despite the 
small number of patients (n= 40). FBT also prolonged BMPFS, 
but not OSBM, in HR-negative/HER2-positive patients. It is 
assumed that there were too few patients with this subtype 
(n= 16) to detect a significant change.
On multivariate analyses for OSBM and BMSS, the FBT pa-
tients did not show a better outcome than that shown by non-
FBT patients, whereas FBT was a significant prognostic factor 
for both on univariate analyses. This might be associated with 
patient selection bias because the treatment modalities em-
ployed for BM largely depended on its extent; the limited num-
ber of patients in the study might also have influenced this re-
sult.
Nevertheless, our findings support the general guidelines for 
BM management, which recommend FBT for limited metastatic 
tumors in the brain. There is a paucity of data to suggest that 
these treatments may improve survival in clinical practice. Our 
study highlights that surgery could improve outcomes for local 
control of BM, regardless of the number of lesions present. These 
results support current guidelines and contribute to optimiza-
tion of treatment modalities for BM in breast cancer patients.
Previous studies have reported several risk factors associated 
with the development of BM, such as young age (< 40 years), 
high tumor grade, ER negativity, TN subtype, and HER2 over-
expression [6,13-15]. Our results show a higher prevalence of 
ER negativity and HER2 overexpression in the general breast 
cancer population. Among the study population, ER positivity 
was seen in 57 patients (49.1%). Approximately 65% of all 
breast cancer patients are thought to be ER-positive; our study 
showed a lower rate of ER positivity in BM patients. Our data 
also showed a higher prevalence of HER2 overexpression (47 
patients, 40.5%) and TN breast cancer (40 patients, 34.5%) 
than the general breast cancer population (20%–30% and 20%, 
respectively) [6]. Considering prognostic factors, our study 
showed that the TN subtype was a significant factor on univar-
iate analyses for OSBM, BMSS, and BMPFS, but not on multi-
variate analyses. Moreover, we found that a negative PR status 
was a poor prognostic factor for survival after BM in breast 
cancer. The prognostic significance of PR, a well-known bio-
marker for endocrine responsiveness, and an important prog-
nostic marker for ER-positive breast cancer, appears to be sus-
tained even after BM development.
Limitations of this study include bias inherent to the retro-
spective nature of the design. The number of patients in the 
study was limited to those diagnosed with breast cancer BM at 
two institutions between 2005 and 2012. Bias in the study popu-
lation could have confounded the results. Neurocognitive as-
sessments were not available and this could have affected treat-
ment planning, thereby creating a selection bias. The cause of 
death was open to subjective interpretation from reviewing the 
charts. No autopsies were performed to identify the true nature 
of death.
Nevertheless, our study provides unique evidence that dif-
ferent types of local treatment can affect the outcome for con-
trol of BM. Furthermore, FBT could be considered for better 
local control of BM in aggressive subtypes such as the HER2 
and TN. Our data contributes to the optimization of treatment 
modalities for BM in breast cancer.
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